RO4929097 γ-Secretase inhibitor, also known as RO-4929097, is a small molecule drug that acts as an inhibitor of the γ-secretase enzyme. This enzyme is involved in the cleavage of amyloid precursor protein (APP) into β-amyloid peptides, which are believed to play a significant role in the development of Alzheimer's disease. RO4929097 was developed by Roche Pharmaceuticals and has been the subject of several clinical trials for the treatment of various types of cancer and Alzheimer's disease.
Chemical name The chemical name of RO4929097 is N-(2-(dimethylamino)ethyl)-6-{5-[4-(1-methyl-1H-imidazol-5-yl)pyrimidin-2-yl]amino-1H-indazol-3-yl}pyridazine-3-carboxamide.
Molecular formula The molecular formula of RO4929097 is C27H30N8O.
Formula weight The formula weight of RO4929097 is 482.58 g/mol.
CAS No. The CAS number of RO4929097 is 847925-91-1.
Top ten keywords from Google and Synonyms
Synonyms:
Health benefits of this product RO4929097 has been studied for its potential therapeutic benefits in the treatment of Alzheimer's disease and various types of cancer. In Alzheimer's disease, the drug works by inhibiting the γ-secretase enzyme, which is responsible for producing β-amyloid peptides that form plaques in the brain. By reducing the production of β-amyloid peptides, RO4929097 may be able to slow or even halt the progression of Alzheimer's disease.
In cancer, RO4929097 works by inhibiting the Notch signaling pathway, which plays a crucial role in cell proliferation and survival. By blocking this pathway, RO4929097 may be able to prevent the growth and spread of cancer cells, making it a promising candidate for cancer treatment.
Potential effects The potential effects of RO4929097 include:
Product mechanism RO4929097 works by inhibiting two different enzymes: γ-secretase and presenilin. These enzymes are involved in the processing of amyloid precursor protein (APP), which is found in high levels in the brains of Alzheimer's patients. When APP is processed by these enzymes, it produces β-amyloid peptides that form plaques in the brain. By inhibiting these enzymes, RO4929097 reduces the production of β-amyloid peptides and slows or halts the progression of Alzheimer's disease.
In cancer, RO4929097 works by inhibiting the Notch signaling pathway, which is involved in cell proliferation and survival. By blocking this pathway, RO4929097 may be able to prevent the growth and spread of cancer cells, making it a promising candidate for cancer treatment.
Safety RO4929097 has been studied in several clinical trials for both Alzheimer's disease and cancer. While the drug has shown promise in these studies, it is not without side effects. Some of the most common side effects reported in clinical trials include gastrointestinal issues (e.g., nausea, vomiting, diarrhea), fatigue, and skin rash. In rare cases, more serious side effects such as liver toxicity have been reported.
Dosing information The optimal dosing of RO4929097 varies depending on the condition being treated and the patient's individual needs. Doses ranging from 10 mg to 80 mg have been studied in clinical trials for Alzheimer's disease and doses up to 60 mg have been studied in trials for cancer. However, the optimal dose has yet to be determined and further research is needed to establish safe and effective dosing guidelines.
